First test based on license to SOMAmer technology now available from Quest Diagnostics

9/18/2012

 

The first commercially available laboratory-developed testing (LDT) testing service to use SomaLogic’s SOMAmer protein measurement technology is now available through our collaborator, Quest Diagnostics, the world’s leading diagnostic testing company. Quest incorporated the SOMAmer technology into its novel clinical testing service. This testing service measures free (i.e., not bound by drug) Epidermal Growth Factor Receptor, in patients receiving particular cancer treatments. Quest Diagnostics’ clinical laboratory in San Juan Capistrano, CA, developed, validated and offers the testing service to clinicians in the United States. For more information, please visit Quest’s website.